methotrexate has been researched along with Hereditary Autoinflammation Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argyropoulou, OD; Bakasis, AD; Bitzogli, K; Chatzis, LG; Cinoku, II; Fotiadis, DI; Gazi, S; Georgountzos, AI; Goules, AV; Katechis, S; Katsifis, G; Katsimpari, C; Liossis, SN; Mavrommati, M; Moutsopoulos, HM; Papagoras, C; Pezoulas, V; Sfontouris, CI; Skopouli, FN; Stergiou, IE; Tzioufas, AG; Venetsanopoulou, AI; Vlachoyiannopoulos, PG; Voulgari, PV | 1 |
1 other study(ies) available for methotrexate and Hereditary Autoinflammation Diseases
| Article | Year |
|---|---|
A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Topics: 2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; Autoimmune Diseases; BNT162 Vaccine; COVID-19; Female; Greece; Hereditary Autoinflammatory Diseases; Humans; Immunoglobulin G; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Prospective Studies; Rheumatic Diseases; Rituximab; SARS-CoV-2; Young Adult | 2021 |